乌司他丁联合川芎嗪对肝脏缺血再灌注损伤保护效应的临床研究

目的：探讨乌司他丁联合川芎嗪对肝脏缺血再灌注损伤的保护作用。方法：选择54例患者,将其随机分为A、B、C3组,A组为肝门阻断前经胃网膜右静脉推注0.9%氯化钠溶液30ml;B组为肝门阻断前经胃网膜右静脉缓慢注射乌司他丁20WU（0.9%氯化钠溶液30ml稀释）;C组为乌司他丁和川芎嗪联合使用,是在B组的基础上加用川芎嗪4ml（0.9%氯化钠溶液25ml稀释）。结果：在3组血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBiL）、清蛋白（Alb）含量的变化中,A组与B组比较,差异有统计学意义（P〈0.01）,C组与B组比较,差异有统计学意义（P〈0.05）。在肝组织中一氧化氮（NO）、丙二荃（MDA）含量的变化中,B组较A组明显升高（P〈0.01）;C组虽高于A组,但低于B组（P〈0.05）。结论：乌司他丁和川芎嗪联合使用对肝脏缺血再灌注损伤具有一定的保护作用,且具有明显的协同作用。

Clinical study of the protective effect of the ulinastatin combined with ligustrazine on hepatic ischemia-reperfusion injury

Objective： To explore the ulinastatin combined with ligustrazine on hepatic ischemia-reperfusion injury. Methods： Selected 54 patients, and they were randomly divided into three groups, group A were treated by former intravenous injection of the right gastroepiploic saline 30 ml; Group B were treated by slow intravenous injection of the right gastroepiploic ulinastatin 20 WU （normal saline 30 ml diluted）; Group C were added 4 ml ligustrazine（diluted with normal saline 25 ml）on the basis of group B. Results： The serum ALT, AST, TBiL, Alb content changes in three groups, group A and group B had a significant difference （P0.01）, Group C and Group B had a significant difference （P0.05）. In the liver tissue content changes of NO,MDA,Group B were higher than those of group A,there were significant difference （P0.01）; Group C were higher than those of group A, but lower than those of group B（P0.05）. Conclusion： Ulinastatin combined with ligustrazine in the treatment for hepatic ischemia-reperfusion injury has protective effects,and has obvious synergies.